Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
2024

Targeting KRAS Mutations in Lung Cancer

Sample size: 126 publication 10 minutes Evidence: moderate

Author Information

Author(s): Dekker Simone E., Deng Lei

Primary Institution: University of Washington

Hypothesis

Can novel KRAS-targeting drugs improve outcomes for patients with KRAS G12C-mutated lung cancer?

Conclusion

New KRAS-targeting drugs show promise, but their efficacy is still not optimal.

Supporting Evidence

  • KRAS G12C is the first druggable KRAS mutation.
  • Sotorasib and adagrasib are FDA-approved drugs for KRAS G12C.
  • Clinical trials show promising early data for novel therapeutic approaches.
  • Resistance to KRAS G12C inhibitors is a significant challenge.
  • Combination therapies are being explored to enhance efficacy.

Takeaway

Scientists are trying to find better medicines for lung cancer caused by a common gene change called KRAS. Some new medicines are helping, but we need even better ones.

Methodology

The review discusses advances and challenges in targeting KRAS mutations in NSCLC, focusing on small molecule inhibitors and clinical trials.

Potential Biases

Potential bias due to the small sample sizes and the nature of clinical trials.

Limitations

The efficacy of first-generation KRAS G12C inhibitors is modest compared to other targeted therapies.

Participant Demographics

Patients with KRAS G12C mutations, primarily adults aged 18 and older.

Statistical Information

P-Value

0.66

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/cancers16223885

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication